ADRB1 and acute coronary syndrome: The aim of this study was to measure anti-β1AR Ab in patients with confirmed acute coronary syndromes (ACS) and compare levels to those in both healthy controls and patients with PET/CT-proven atherosclerosis in the absence of an ACS.